ITM Isotope Technologies Munich SE

ITM Isotope Technologies Munich is preparing the complex logistics and manufacturing it will need for commercial launch of ITM-11 (non-carrier-added 177 Lu-edotreotide), its radiopharmaceutical candid

The market for targeted radiotherapy in oncology could soon become a bit more competitive as ITM Isotope Technologies Munich unveiled topline Phase III results for ITM-11 (non-carrier-added 177 Lu-edo

The radiopharmaceutical space saw a couple of huge deals at the end of last year, and another flurry, albeit on a rather smaller scale, happened this week. On September 12, both Sanofi and ITM Isot

The road to starting up and funding a new biopharmaceutical venture is paved with plenty of speedbumps, but certain big pharma companies and investors have made efforts to smooth the path for start-up